Development of CDK4/6 Inhibitors: A Five Years Update

Area of Science:

• Oncology
• Pharmacology
• Medicinal Chemistry

Background:

• Metastatic breast cancer often develops resistance to aromatase inhibitors.
• Cyclin-dependent kinases 4 and 6 (CDK4/6) are key regulators of cell cycle progression.
• Approved CDK4/6 inhibitors combined with endocrine therapy have significantly improved survival in breast cancer.

Purpose of the Study:

• To review recent advancements in the development of novel selective CDK4/6 inhibitors.
• To explore small-molecule inhibitors and proteolysis-targeting chimeras (PROTACs) for enhanced cancer treatment.
• To analyze structure-activity relationships, kinase selectivity, and antiproliferative effects of new inhibitors.

Main Methods:

• Literature review of recent studies on CDK4/6 inhibitors.
• Analysis of structure-activity relationships for small-molecule inhibitors.
• Evaluation of PROTACs as an emerging therapeutic strategy.
• Assessment of kinase selectivity and antiproliferative activity data.

Main Results:

• Several new selective CDK4/6 inhibitors demonstrate improved efficacy and safety profiles.
• PROTACs targeting CDK4/6 represent a promising novel approach.
• Structure-activity relationship studies guide the design of more potent and selective inhibitors.

Conclusions:

• Ongoing research aims to develop next-generation CDK4/6 inhibitors with superior clinical profiles.
• Targeting CDK4/6 remains a critical strategy for overcoming endocrine resistance in breast cancer.
• Future developments may include combination therapies and novel drug delivery systems.